Featured Article

Managing Bisphosphonate Drug Holidays in Patients With Osteoporosis

Managing Bisphosphonate Drug Holidays in Patients With Osteoporosis

Ongoing treatment with bisphosphonate therapy may not be needed to prevent future fractures in certain patients due to the sustained effect of the drug.

Latest News

Niacin Intake May Be Linked to Hip Fracture Risk in Older Adults

Niacin Intake May Be Linked to Hip Fracture Risk in Older Adults

Both high and low niacin intake was associated with a risk for incident hip fractures in older adults.

Serum Estradiol Levels Predictive of Fractures During Menopausal Transition

Serum Estradiol Levels Predictive of Fractures During Menopausal Transition

Measuring serum estradiol during the menopausal transition might help identify women at higher risk for fractures.

BMD Improved Significantly With Denosumab vs Bisphosphonates in Osteoporosis

BMD Improved Significantly With Denosumab vs Bisphosphonates in Osteoporosis

Results from a meta-analysis show that denosumab improved bone mineral density significantly more than bisphosphonates at the lumbar spine, total hip, and femoral neck.

Vertebral Fracture Assessment Imaging May Predict Incident Fractures

Vertebral Fracture Assessment Imaging May Predict Incident Fractures

Researchers examined the associations of prevalent vertebral fracture identified on vertebral fracture assessment images in routine practice with incident fractures.

Evidence Lacking for Benefit of Surgery for Vertebral Fractures

Evidence Lacking for Benefit of Surgery for Vertebral Fractures

Surgical procedures do not appear to provide significant benefit for patients with vertebral fractures.

Vitamin D, Calcium May Improve BMD in Postmenopausal Women With RA, Osteoporosis

Vitamin D, Calcium May Improve BMD in Postmenopausal Women With RA, Osteoporosis

Bone mineral density measures were significantly greater at 3 years in postmenopausal women with comorbid osteoporosis and rheumatoid arthritis who were given vitamin D and calcium supplementation.

Gender-Affirming Hormonal Treatment and Long-Term Bone Safety

Gender-Affirming Hormonal Treatment and Long-Term Bone Safety

Gender-affirming hormonal treatment does not negatively affect bone mineral density in transgender people.

Trends in Bisphosphonate Use and Nationwide Hip Fracture Rates

Trends in Bisphosphonate Use and Nationwide Hip Fracture Rates

Total use of medications for treating osteoporosis in Denmark reached a plateau in 2014, and hip fracture rates declined by 30% from 2005 to 2015.

FDA Panel Votes on Novel Osteoporosis Treatment Evenity

FDA Panel Votes on Novel Osteoporosis Treatment Evenity

In the Biologics License Application (BLA) resubmission, Amgen and UCB proposed to narrow the indication to treatment of osteoporosis in postmenopausal women at high risk of fracture.

Denosumab Reduces Bone Turnover by Inhibiting Osteoclast Formation, Activity in Cortical Bone

Denosumab Reduces Bone Turnover by Inhibiting Osteoclast Formation, Activity in Cortical Bone

Denosumab inhibits osteoclast formation and activity in cortical bone, and this mechanism of action may be reflected by the reduction of erosion in both depth and surface.

Sign Up for Free e-newsletters